Showing results (91-100 of 128) with videos related to
Sort By:
Pageof 13
Journal of the National Cancer Institute|December 8, 2005
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of actionYan Zhou, Celia Garcia-Prieto, Dennis A Carney, et al.Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoirDane J Clausen, Jian Liu, Wensheng Yu, et al.Bioorganic & Medicinal Chemistry Letters|July 17, 2017
Development of a prodrug of hydantoin based TACE inhibitorLing Tong, Seong Heon Kim, Lei Chen, et al.Bioorganic & Medicinal Chemistry Letters|August 15, 2021
Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffoldWensheng Yu, Yongqi Deng, David Sloman, et al.ACS Medicinal Chemistry Letters|December 18, 2020
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding GroupJian Liu, Younong Yu, Joseph Kelly, et al.Journal of Medicinal Chemistry|October 30, 2016
Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated VariantsWensheng Yu, Ling Tong, Bin Hu, et al.Bioorganic & Medicinal Chemistry Letters|April 26, 2020
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivationWensheng Yu, Jian Liu, Younong Yu, et al.ACS Medicinal Chemistry Letters|July 18, 2020
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for ClearanceJian Liu, Joseph Kelly, Wensheng Yu, et al.Journal of Medicinal Chemistry|April 2, 2021
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG ActivityWensheng Yu, Jian Liu, Dane Clausen, et al.Bioorganic & Medicinal Chemistry Letters|February 1, 2011
II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonistsYuefei Shao, Gopinadhan N Anilkumar, Carolyn Diianni Carroll, et al.Pageof 13